Overview

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.
Details
Lead Sponsor:
Pfizer